AR and posterior cortical atrophy: During the development of PCa, AR undergoes a functional switch toward oncogenic activity; this can often be successfully antagonized with treatments such as systemic androgen deprivation, androgen synthesis inhibitors, or other direct AR-targeted therapies [3,4,5,6].